OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice

Brca Mutation ◽

Single Agent ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Germline Brca Mutation ◽

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Case Medical Research ◽

10.31525/ct1-nct04296370 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Brca Mutation ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Chemotherapy Treatment ◽

Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

10.1158/1538-7445.sabcs19-pd4-03 ◽

2020 ◽

Cited By ~ 1

Author(s):

Mark Robson ◽

Seock-Ah Im ◽

Elżbieta Senkus ◽

Binghe Xu ◽

Susan Domchek ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1045 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1045-1045 ◽

Cited By ~ 1

Author(s):

Mark E. Robson ◽

Kathryn Jean Ruddy ◽

Seock-Ah Im ◽

Elzbieta Senkus-Konefka ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Eortc Qlq C30 ◽

Germline Brca Mutation ◽

Eortc Qlq

OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC)

Annals of Oncology ◽

10.1093/annonc/mdx365.053 ◽

2017 ◽

Vol 28 ◽

pp. v96 ◽

Cited By ~ 2

Author(s):

M. Robson ◽

K.J. Ruddy ◽

S-A. Im ◽

E. Senkus-Konefka ◽

B. Xu ◽

...

Keyword(s):

Brca Mutation ◽

Single Agent ◽

Metastatic Breast ◽

Health Related Quality ◽

Chemotherapy Treatment ◽

Related Quality ◽

Health Related ◽

Germline Brca Mutation ◽

Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1052 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1052-1052 ◽

Cited By ~ 2

Author(s):

Nadine M. Tung ◽

Seock-Ah Im ◽

Elzbieta Senkus-Konefka ◽

Binghe Xu ◽

Susan M. Domchek ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Visceral Metastases ◽

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz012 ◽

2019 ◽

Vol 30 (4) ◽

pp. 558-566 ◽

Cited By ~ 89

Author(s):

M.E. Robson ◽

N. Tung ◽

P. Conte ◽

S.-A. Im ◽

E. Senkus ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

New England Journal of Medicine ◽

10.1056/nejmx170012 ◽

2017 ◽

Vol 377 (17) ◽

pp. 1700-1700 ◽

Cited By ~ 6

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Abstract OT1-1-14: A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)

10.1158/1538-7445.sabcs14-ot1-1-14 ◽

2015 ◽

Author(s):

Nicholas C Turner ◽

Judith Balmana ◽

Susan M Domchek ◽

Frances Visco ◽

Charlie Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Brca Mutation ◽

Parp Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Abstract P6-18-19: Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy - A comparison with MONARCH 1

10.1158/1538-7445.sabcs18-p6-18-19 ◽

2019 ◽

Author(s):

H Rugo ◽

V Dieras ◽

J Cortes ◽

D Patt ◽

H Wildiers ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Single Agent ◽

Metastatic Breast ◽

Heavily Pretreated ◽

Pretreated Patients ◽

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4592-y ◽

2017 ◽

Vol 168 (2) ◽

pp. 337-348 ◽

Cited By ~ 2

Author(s):

Y. F. Yu ◽

Y. Wang ◽

T. P. Fu ◽

K. Chen ◽

J. Q. Liu ◽

...

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽